INLEXZO (Gemcitabine Hydrochloride) Patent Expiration, LOE Window & CMS Spending

INLEXZO (Gemcitabine Hydrochloride) by Johnson & Johnson: FDA Orange Book core substance LOE 2034-08-19 (last listed 2038-11-07), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $69,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN219683 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-08-19
Last Listed Patent or Exclusivity Date2038-11-07
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($69,000 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.